Home
About Us
Products & Pipeline
News
Careers
contact us
contact us
See our latest news
News
July 25, 2024
Kashiv BioSciences Announces Completion of Enrollment for Phase III Clinical Trial of ADL018, a Biosimilar Candidate to XOLAIR® (omalizumab)
July 1, 2024
Kashiv BioSciences Enters into Exclusive Licensing Agreement with Amneal for Commercialization of a Proposed Biosimilar to XOLAIR® (Omalizumab)
October 3, 2023
Kashiv BioSciences Enters into Exclusive Licensing Agreement with Alvotech for Development & Commercialization of a Proposed Biosimilar to Xolair® (omalizumab)
October 2, 2023
Kashiv BioSciences Enrolls First Patient in Phase III Clinical Study for ADL018, A Biosimilar Candidate to Xolair® (omalizumab)
July 5, 2023
Kashiv Biosciences Announces Successful Phase 1 Study Results of ADL018, A Biosimilar Candidate to Xolair® (omalizumab)
May 31, 2022
Kashiv BioSciences Achieves Second U.S. Biosimilar Approval with FYLNETRA® (pegfilgrastim-pbbk)
March 2, 2022
Kashiv BioSciences Receives Approval for Its First Biosimilar Releuko™ (filgrastim-ayow)
We’re here to help!
Reach out to us and our team will get back to you shortly.
Contact us
